Thank you for your inquiry regarding Otonomy’s clinical trials for our tinnitus product candidate, OTO-311. The FDA has cleared the company's Investigational New Drug application (IND) for OTO-311. The IND clearance enables Otonomy to initiate a Phase 1 dose escalation clinical safety trial of OTO-311 in a small number of volunteers who do not have tinnitus. Timing for initiating a Phase 2 trial for OTO-311 in patients with tinnitus is scheduled for the end of this year. I am not able to address your other questions as the protocol has not been completed.If you are interested, you can add your name to a database to receive future communications from the company related to clinical trials and program updates by registering here If you would like to receive alerts of news announcements from the company, you can register for alerts on the Otonomy website For information about other trials available for tinnitus patients, you can periodically check the clinicaltrials.gov website, searching for "tinnitus" to identify trials that are enrolling.Regards,Dean Hakanson MDChief Medical Officer​